Back Knudsen, LB, Nielsen, PF, Huusfeldt, PO, et al (2000) 'Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration', Journal of Medicinal Chemistry , 43, 1664-69
While not appropriate for every patient, they fill an important gap for people whose local providers are unfamiliar with or resistant to obesity pharmacotherapy
Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
Consistency: A patch delivers a steady dose of medication throughout the day, helping maintain stable levels in the bloodstream
People who are obese (have a BMI greater than or equal to 30) are clinically eligible for GLP-1 drugs, but employer plans may set additional BMI requirements to cover GLP-1 drug use under obesity
Our team specializes in hormonal disorders, including diabetes, as well as weight loss management